Skip to main content
Fig. 1 | Pediatric Rheumatology

Fig. 1

From: Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis

Fig. 1

(A) Cost-effectiveness acceptability frontier (based on 1000 bootstrap iterations) indicating the probability of the optimal treatment option being cost-effective across different willingness-to-pay (WTP) thresholds per month in clinically inactive disease (CID) and (B) per quality-adjusted life-year (QALY) gained. C Incremental cost-effectiveness ratio (ICER) of infliximab plus methotrexate (IFX) vs. TRIPLE (methotrexate, hydroxychloroquine, and sulphasalazine) as function of infliximab price. D ICER of infliximab plus methotrexate (IFX) vs. methotrexate monotherapy (MTX)

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096